Exploration of the mechanism of colorectal cancer metastasis using microarray analysis

Chen, Shuo; Wang, Yan; Zhang, Lin; Su, Yinan; Zhang, Mingqing; Wang, Juan

doi:10.3892/ol.2017.7044

Cited by 10 publications

(9 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 In addition, a recent microarray analysis indicated that FNDC3B was highly expressed in CRC and was suggested as a prognostic and therapeutic target of CRC, which was further verified in our study. 10 FNDC3B is initially known as a modulator of differentiation of osteoblast and adipocyte. 21 Recently, the role of FNDC3B in cancer biology was emerged as the accumulating evidence indicated that FNDC3B regulated the growth and development of diversified human tumors.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

<p>FNDC3B, Targeted by miR-125a-5p and miR-217, Promotes the Proliferation and Invasion of Colorectal Cancer Cells via PI3K/mTOR Signaling</p>

Yang

Wang

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Fibronectin type III domain containing 3B (FNDC3B) acts as an oncogene in various cancers, and abnormal expression of FNDC3B has been found in colorectal cancer (CRC). Our study aimed to illustrate the role of FNDC3B in CRC development. Methods: Through RT-qPCR and western blotting assays, the mRNA and protein expressions of target genes were measured. CCK-8 and MTT methods were used to detect cell proliferation. Invasion ability was determined using Transwell assay. TargetScan platform and luciferase reporter gene assay were performed to predict and validate the bindings between FNDC3B and miR-125a-5p or miR-217. Besides, the expression correlation was measured by Pearson's Correlation analysis. Results: We found that FNDC3B was significantly upregulated in CRC tissues and tumor cell lines, and high expression of FNDC3B predicted a poor survival outcome. The bindings between FNDC3B and miR-125a-5p and miR-217 were respectively at the motifs of CUCAGGG and AUGCAGU. MiR-125a-5p and miR-217 were downregulated in CRC tissues, and both were negatively correlated with FNDC3B expression. Subsequently, the downregulated miR-125a-5p and miR-217 were confirmed as contributors FNDC3B upregulation in CRC. A loss-of-function assay demonstrated that FNDC3B knockdown inhibited the proliferation of CRC cells, while FNDC3B overexpression promoted the proliferation and invasion of tumor cells. Besides, we validated that PI3K/mTOR signaling was involved in the regulation of FNDC3B on the proliferation and invasion of CRC cells. Conclusion: Generally, our findings demonstrated that FNDC3B facilitated cell proliferation and invasion via PI3K/mTOR signaling, and further promoted CRC progression. The novel miR-125a-5p/FNDC3B and miR-217/FNDC3B axes might be new targets for CRC prognosis and therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…9 An exploration of CRC mechanism using microarray analysis revealed that FNDC3B was an upregulated gene in CRC. 10 However, the biological function of FNDC3B in the growth and metastasis of CRC tumors remains indistinct.…”

Section: Introductionmentioning

confidence: 99%

<p>FNDC3B, Targeted by miR-125a-5p and miR-217, Promotes the Proliferation and Invasion of Colorectal Cancer Cells via PI3K/mTOR Signaling</p>

Yang

Wang

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…34 Besides, pathways in cancer also play a critical role in CRC metastasis. 35 However, more research is warranted to elucidate the precise molecular mechanisms of exosomal miRNAs in mCRC.…”

Section: Discussionmentioning

confidence: 99%

Tumor‐derived exosomal miRNA‐320d as a biomarker for metastatic colorectal cancer

Tang

Zhao

Song

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background To identify specific exosomal microRNAs (miRNAs) as serum biomarkers for prediction of metastasis in patients with colorectal cancer (CRC). Materials and Methods Serum exosomes were isolated from patients with metastatic CRC (n = 34) and non‐metastatic CRC (n = 108) by ultracentrifugation and characterized using transmission electron microscopy, qNano, and Western blot. Differential exosomal miRNAs were screened by sequencing and validated by qPCR in metastatic and non‐metastatic CRC patients. Results After sequence analysis, KEGG analysis showed that differential genes were associated with Rap1 signaling pathway and pathways in cancer, 6 upregulated exosomal miRNAs (miR‐224‐5p, miR‐548d‐5p, miR‐200a‐3p, miR‐320d, miR‐200b‐3p, and miR‐1246), and 3 downregulated exosomal miRNAs (novel_246, novel_301, and miR‐27a‐5p) were screened with fold change >1.5, among which miR‐320d was selected as the best candidate involved in CRC metastasis. Validation analysis revealed exosomal miR‐320d could significantly distinguish metastatic from non‐metastatic CRC patients (P = .019), with AUC of 0.633 for the diagnosis of patients with metastatic CRC. Besides, the combination of miR‐320d and CEA had an area under curve (AUC) of 0.804 for the diagnosis of patients with metastatic CRC. Conclusion Serum exosomal miR‐320d is a promising non‐invasive diagnostic biomarker for distinguishing metastatic from non‐metastatic CRC.

show abstract

“…For subtype c6, 163 DEGs (22 up-regulated and 141 down-regulated) were identified as representative genes and were enriched in glycosaminoglycan biosynthesis-heparan sulfate, tight junction, circadian rhythm, ECM-receptor interaction and so on. Glycosaminoglycans have therapeutic value in cancer [ 56 ]; tight junction whose protein claudin-2 has been reported as a potential target for CRC therapy [ 57 ]; circadian rhythm plays roles in the pathogenesis of CRC [ 58 ]; ECM-receptor interaction may play a critical role in CRC metastasis [ 59 ]. In addition, copy loss of ARHGEF28 , BIN2P2 , and SLC25A5P9 were frequent in subtype c6, which suggested that they may be the potential biomarkers.…”

Section: Discussionmentioning

confidence: 99%

Network-based identification of biomarkers for colon adenocarcinoma

Wang

Yang

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: As one of the most common cancers with high mortality in the world, we are still facing a huge challenge in the prevention and treatment of colon cancer. With the rapid development of high throughput technologies, new biomarkers identification for colon cancer has been confronted with the new opportunities and challenges. Methods: We firstly constructed functional networks for each sample of colon adenocarcinoma (COAD) by using a sample-specific network (SSN) method which can construct individual-specific networks based on gene expression profiles of a single sample. The functional genes and interactions were identified from the functional networks, respectively. Results: Classification and subtyping were used to test the function of the functional genes and interactions. The results of classification showed that the functional genes could be used as diagnostic biomarkers. The subtypes displayed different mechanisms, which were shown by the functional and pathway enrichment analysis for the representative genes of each subtype. Besides, subtype-specific molecular patterns were also detected, such as subtype-specific clinical and mutation features. Finally, 12 functional genes and 13 functional edges could serve as prognosis biomarkers since they were associated with the survival rate of COAD. Conclusions: In conclusion, the functional genes and interactions in the constructed functional network could be used as new biomarkers for COAD.

show abstract

Exploration of the mechanism of colorectal cancer metastasis using microarray analysis

Cited by 10 publications

References 44 publications

<p>FNDC3B, Targeted by miR-125a-5p and miR-217, Promotes the Proliferation and Invasion of Colorectal Cancer Cells via PI3K/mTOR Signaling</p>

<p>FNDC3B, Targeted by miR-125a-5p and miR-217, Promotes the Proliferation and Invasion of Colorectal Cancer Cells via PI3K/mTOR Signaling</p>

Tumor‐derived exosomal miRNA‐320d as a biomarker for metastatic colorectal cancer

Network-based identification of biomarkers for colon adenocarcinoma

Contact Info

Product

Resources

About